News

Sarepta Therapeutics president and CEO Chris Garabedian said the agreement will lead to development of new treatment options for influenza with new mechanisms of action with limitations of

The patents cover company’s tamper-resistant platforms, designed to resist dose dumping of orally delivered opioids and may sequester and bring down drug release of a drug, which has

According to the deal, Yuhan can leverage CEVEC’s CAP-T and CAP cell expression systems in the production and development of a range of therapeutic proteins. CEVEC CEO Wolfgang

The collaboration will focus on developing Pfizer biologics, leveraging Halozyme’s drug delivery platform Enhanze technology that is based on the company’s recombinant human hyaluronidase enzyme (rHuPH20). Pfizer BioTherapeutics

As part of the transaction, the company will transfer 13 of its portfolio company holdings to a new private holding company, KDev Investments, which will include portfolio of

Fast Track facilitates the development and expedites the review of new drugs intended to serve unmet medical needs in serious or life-threatening conditions. Lexicon Pharmaceuticals senior vice president

As part of the agreement, Cosmo Pharmaceuticals, using its proprietary MMX technology will formulate new human monoclonal antibodies generated by AIMM Therapeutics in an extended release form. AIMM

ImmunoGen president and CEO Daniel Junius said major healthcare companies are interested in developing multiple product candidates with TAP technology. "In recent years, there has been a marked

Established in 1987, HCR is headquartered in Munich, Germany and operates across Europe, Israel and South America in addition to a US office in Princeton, New Jersey. With